Cepheid (CPHD) 47.93 $CPHD
Cepheid Reports 2014 First Quarter Results
PR Newswire - Thu Apr 17, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today reported revenues for the first quarter of 2014 of $106.9 million, representing growth of 16% from $91.9 million for the first quarter of 2013. Net loss in the first quarter of 2014 was $(9.3) million, or $(0.13) per share, which compares to net income of $0.3 million, or $0.00 per share, in the first quarter of 2013.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Forthcoming Earnings Release Calendar -- Research on AutoNation, Baxter Intl., Cepheid, and BlackRock
PR Newswire - Thu Apr 10, 10:04AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: AutoNation Inc. (NYSE: AN), Baxter International Inc. (NYSE: BAX), Cepheid Inc. (NASDAQ: CPHD) and BlackRock Inc. (NYSE: BLK). Full earnings notes on AN, BAX, CPHD and BLK can be downloaded upon signing up at:
Cepheid (CPHD) Looks Good: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:04AM CDT
Cepheid was a big mover last session, as the company saw its shares rise over 5% on the day.
Cepheid Announces European Release of Xpert Norovirus, the First On-Demand Molecular Test for Detection of Norovirus
PR Newswire - Thu Apr 10, 6:00AM CDT
Cepheid (NASDAQ: CPHD) today announced the release of Xpert® Norovirus, a qualitative in vitro diagnostic test for rapid identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII), to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform.
Upgrade Alert for Cepheid (CPHD)
Comtex SmarTrend(R) - Wed Apr 09, 7:01AM CDT
Cepheid (NASDAQ:CPHD) was upgraded from Market Perform to Outperform at JMP Securities today. The stock closed yesterday at $47.74 on volume of 695,000 shares, above average daily volume of 652,000. Cepheid, Inc. develops, manufactures, and markets microfluidic systems for analyzing nucleic acids in blood, urine, and other substances. The Company's technology is designed to detect infinitesimal amounts of disease-causing agents and contaminants in food and water and purify DNA and perform genetic profiling.
Insider Trading Alert - MPWR, CPHD And MKL Traded By Insiders
at The Street - Tue Apr 08, 9:01AM CDT
Stocks with insider trader activity include MPWR, CPHD and MKL
Gene Expression Reagent Trends - Global Market Report 2014
M2 - Mon Apr 07, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3lbtf8/gene_expression) has announced the addition of the "Gene Expression Reagent Trends" report to their offering. Gene Expression refers to the production of functional products, most commonly proteins, using information saved in a specific gene. Gene expression is a key process undertaken by all life forms, including unicellular as well as multicellular organisms, primarily for generating their macromolecular machinery. The report analyzes and presents an overview of Gene Expression Reagents market worldwide. Supported with 3 market data tables, the report provides a review of global market trends, and various strategic industry activities of major companies witnessed by the industry over the last few years. Key Topics Covered: 1. GENE EXPRESSION REAGENTS - AN OVERVIEW 2. RECENT INDUSTRY ACTIVITY - Sigma-Aldrich Inks Agreement with Olink Bioscience - Synpromics Receives Grant from Technology Strategy Board - Thermo Fisher Scientific to Acquire Life Technologies - Agilent Technologies Inks Licensing Agreement with SRI International - Agilent Technologies Inks Agreement with Roche - ZyGEM Corp Signs Agreement with Quanta BioSciences - Affymetrix Receives US FDA Clearance for Gene Profiling Reagents 3. PRODUCT LAUNCHES/TECHNOLOGICAL INNOVATIONS - Agilent Technologies Launches SureScanDx Microarray Scanner - Illumina Introduces Universal Real-Time PCR Reagent Portfolio - Life Technologies Introduces Compendia Oncomine? Next - Generation Sequencing Power Tools - Mirus Bio Develops TransIT-BrCa Transfection Reagent - Affymetrix Launches Axiom? Genotyping Arrays - Affymetrix Introduces SensationPlus FFPE Reagent Kit - Agilent Technologies Unveils Agilent SurePrint G3 Human Gene Expression v2 Microarray - Agilent Unveils Agilent CytoGenomics 1.0 - Agilent Technologies Introduces GeneSpring GX 11. - Bioinformatics Software - Agilent Technologies Unveils New Exon Analysis Solution 4. MARKET PARTICIPANTS - Affymetrix, Inc. - Agendia, Inc. - Agilent Technologies, Inc. - Applied Biosystems, Inc. - Cepheid - Clontech Laboratories, Inc. - Complete Genomics, Inc. - Cytocell Ltd. - DNA LandMarks, Inc. - DNAVision SA - Dynex Technologies, Inc. - Epicentre? Biotechnologies - Eurofins Medigenomix GmbH - Eurogentec SA - Exiqon A/S - GE Healthcare - Geneworks Pty., Ltd. - Genisphere LLC - Illumina, Inc. - Inqaba Biotechnical Industries Pty., Ltd. - Life Technologies Corporation - Mirus Bio LLC - Ocimum Biosolutions Ltd. - Origene Technologies, Inc. - Quanta Biosciences, Inc. - Roche Diagnostics - Saturn Biotech Ltd. - Sequetech Corporation - Sigma-Aldrich Co. LLC - Thermo Fisher Scientific, Inc. 5. APPENDIX For more information visit http://www.researchandmarkets.com/research/3l...expression
Global Genomics Market Forecasts & Opportunities to 2018 - Products, Consumables & Services
M2 - Mon Apr 07, 3:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b5sp23/genomics_market) has announced the addition of the "Global Genomics Market Forecasts & Opportunities to 2018 - Products, Consumables & Services" report to their offering. The global genomics market was valued at $11.11 billion in 2013, and is expected to grow at a CAGR of over 12.0% from 2013 to 2018. The penetration of new markets through the expansion of genomics applications, and advancements in existing technologies plays an important role in attracting new market participants to invest in this market. Next Generation Sequencing (NGS) in personalized medicine and molecular diagnostics is considered as a high growth area for the global genomics market. This new technology provides an affordable and accurate screening solution for genetic mutations. Moreover, the increasing volume of novel genetic tests for personalized medicine and biomarker discovery ensures the continued growth of this market. Tier I and Tier II companies were found to be dominant in the instrument and consumables segments of the genomics market. The genomics market is becoming increasingly consolidated. Among all market players, Roche Diagnostics, Life Technologies, and QIAGEN together accounted for over 47.0% of the revenues earned by the global genomics market in 2013. This concentration of market shares with Tier I market players is expected to challenge market growth. However, technological advancements, and increasing investments are expected to continue to drive the growth of the global genomics market. This report provides comprehensive analysis of market dynamics - drivers, restraints, key market metrics, current market trends, competitive structure, and market revenues and forecasts from 2013 to 2018. It also includes an analysis of mergers and acquisitions in the global genomics market over the last ten years, in addition to technology roadmaps for key technology areas in this market. As a part of the premium insights section, current growth strategies adopted by market participants in the global genomics market have been detailed and analyzed. Scope Products - Instruments - NGS platform - Microarray - RT-PCR Consumables - Genechips - Reagents for DNA Extraction & Purification - Sequencing Services - Sequencing & Microarray Services - Software) Key Topics Covered: - Introduction - Executive Overview - Total Global Genomics Market - Global Genomics Market, By Product Segment - Global Genomics Market, By Technology - Global Genomics Market, By Application - Global Genomics Market, By Geography - Mergers And Acquisitions - Competitive Strategies - Company Profiles - Affymetrix, Inc. - Agilent Technologies, Inc. - Bgi - Bio-Rad Laboratories, Inc. - Cepheid - Ge Healthcare - Illumina, Inc. - Life Technologies, Corp. - Qiagen - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/b5...ics_market
Cepheid Schedules 2014 First Quarter Results Announcement and Webcast
PR Newswire - Thu Apr 03, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2014 first quarter ended March 31, 2014 on Thursday, April 17, 2014, after the close of the market.
Cepheid Announces European Release of Xpert HPV, a 60-Minute Test for Cervical Cancer-Related Human Papillomaviruses
PR Newswire - Wed Apr 02, 6:00AM CDT
Cepheid (NASDAQ: CPHD) today announced the release of Xpert® HPV, a 60-minute test for cervical cancer-related human papillomaviruses to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform. Xpert HPV is a multiplexed test that targets the E6 and E7 oncogenes of 14 cancer-related HPV types and specifically calls out high-risk types 16 and 18/45 in separate detection channels, with 11 other high-risk types detected in a combined channel.
Cepheid Shares Up 37.3% Since SmarTrend's Buy Recommendation (CPHD)
Comtex SmarTrend(R) - Mon Mar 31, 9:39AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2013 at $37.72. In approximately 7 months, Cepheid has returned 37.26% as of today's recent price of $51.78.
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Shares of CPHD Up 37.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 24, 9:14AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2013 at $37.72. In approximately 7 months, Cepheid has returned 37.89% as of today's recent price of $52.02.
Cepheid [CPHD] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Mar 21, 9:00AM CDT
What:
In Recognition of World TB Day 2014, Cepheid and American Lung Association to Ring the NASDAQ Stock Market Opening Bell
PR Newswire - Fri Mar 21, 6:00AM CDT
Cepheid (Nasdaq: CPHD) today announced that James Post, Executive Vice President, North America Commercial Operations for Cepheid, and Harold P. Wimmer, National President and CEO of the American Lung Association, will ring the NASDAQ Opening Bell on March 24th 2014 to commemorate World TB Day.
Cepheid and American Lung Association to Reveal Winner of the 'Ride Against TB' Bike at 2nd Annual New York City TB Walk
PR Newswire - Thu Mar 20, 6:00AM CDT
Cepheid (Nasdaq: CPHD) today announced that the winner of the Ride Against TB bike, a prize in the campaign to benefit the American Lung Association, will be revealed at the 2nd annual New York City World TB Day Walk and Rally on March 22nd. At 9:30 a.m. EDT, Paul Teutul Jr. of Paul Jr. Designs will hand over the keys to the winner of the one-of-a-kind PJD bike at the start line of the World TB Day walk. Cody Connelly, of American Chopper fame, will then ride the custom-designed bike to lead walkers from Union Square in the march down Broadway to the TB rally in Washington Square.
Concise Analysis of the International qPCR and dPCR Instrumentation Market
M2 - Tue Mar 18, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f2m2mm/qpcr_and_dpcr) has announced the addition of the "Concise Analysis of the International qPCR and dPCR Instrumentation Market" report to their offering. This report analyzes the worldwide markets for qPCR and dPCR Instrumentation in US$ Million. The Global market is further analyzed by the following Product Segments and End-Use Markets: Product Segments - qPCR (quantitative Polymerase Chain Reaction), and dPCR (digital Polymerase Chain Reaction); End-Use markets - Educational/Research, Testing Laboratories, and Pharma. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 49 companies including many key and niche players such as: - Agilent Technologies - Biofire Diagnostics, Inc. - Bio-Rad Laboratories, Inc. - Cepheid - Eppendorf AG - Exiqon A/S - F. Hoffmann-La Roche Ltd. - Fluidigm Corporation - Illumina, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MAJOR TRENDS & ISSUES 3. COMPETITION 4. END-USE MARKET ANALYSIS 5. PRODUCT OVERVIEW 6. INSIGHT INTO GLOBAL SPENDING ON LIFE SCIENCES RESEARCH 7. PRODUCT INNOVATIONS/ INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. MIDDLE EAST & AFRICA 7. LATIN AMERICA IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 49 (including Divisions/Subsidiaries - 51) - The United States (29) - Canada (1) - Japan (1) - Europe (19) - Germany (7) - The United Kingdom (2) - Spain (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/f2...r_and_dpcr
Uptrend Call Working As Cepheid Stock Rises 42.8% (CPHD)
Comtex SmarTrend(R) - Fri Mar 14, 4:46PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2013 at $37.72. In approximately 6 months, Cepheid has returned 42.82% as of today's recent price of $53.88.
Cepheid Reports 2014 First Quarter Results
PR Newswire - Thu Apr 17, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today reported revenues for the first quarter of 2014 of $106.9 million, representing growth of 16% from $91.9 million for the first quarter of 2013. Net loss in the first quarter of 2014 was $(9.3) million, or $(0.13) per share, which compares to net income of $0.3 million, or $0.00 per share, in the first quarter of 2013.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Forthcoming Earnings Release Calendar -- Research on AutoNation, Baxter Intl., Cepheid, and BlackRock
PR Newswire - Thu Apr 10, 10:04AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: AutoNation Inc. (NYSE: AN), Baxter International Inc. (NYSE: BAX), Cepheid Inc. (NASDAQ: CPHD) and BlackRock Inc. (NYSE: BLK). Full earnings notes on AN, BAX, CPHD and BLK can be downloaded upon signing up at:
Cepheid (CPHD) Looks Good: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:04AM CDT
Cepheid was a big mover last session, as the company saw its shares rise over 5% on the day.
Cepheid Announces European Release of Xpert Norovirus, the First On-Demand Molecular Test for Detection of Norovirus
PR Newswire - Thu Apr 10, 6:00AM CDT
Cepheid (NASDAQ: CPHD) today announced the release of Xpert® Norovirus, a qualitative in vitro diagnostic test for rapid identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII), to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform.
Upgrade Alert for Cepheid (CPHD)
Comtex SmarTrend(R) - Wed Apr 09, 7:01AM CDT
Cepheid (NASDAQ:CPHD) was upgraded from Market Perform to Outperform at JMP Securities today. The stock closed yesterday at $47.74 on volume of 695,000 shares, above average daily volume of 652,000. Cepheid, Inc. develops, manufactures, and markets microfluidic systems for analyzing nucleic acids in blood, urine, and other substances. The Company's technology is designed to detect infinitesimal amounts of disease-causing agents and contaminants in food and water and purify DNA and perform genetic profiling.
Insider Trading Alert - MPWR, CPHD And MKL Traded By Insiders
at The Street - Tue Apr 08, 9:01AM CDT
Stocks with insider trader activity include MPWR, CPHD and MKL
Gene Expression Reagent Trends - Global Market Report 2014
M2 - Mon Apr 07, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3lbtf8/gene_expression) has announced the addition of the "Gene Expression Reagent Trends" report to their offering. Gene Expression refers to the production of functional products, most commonly proteins, using information saved in a specific gene. Gene expression is a key process undertaken by all life forms, including unicellular as well as multicellular organisms, primarily for generating their macromolecular machinery. The report analyzes and presents an overview of Gene Expression Reagents market worldwide. Supported with 3 market data tables, the report provides a review of global market trends, and various strategic industry activities of major companies witnessed by the industry over the last few years. Key Topics Covered: 1. GENE EXPRESSION REAGENTS - AN OVERVIEW 2. RECENT INDUSTRY ACTIVITY - Sigma-Aldrich Inks Agreement with Olink Bioscience - Synpromics Receives Grant from Technology Strategy Board - Thermo Fisher Scientific to Acquire Life Technologies - Agilent Technologies Inks Licensing Agreement with SRI International - Agilent Technologies Inks Agreement with Roche - ZyGEM Corp Signs Agreement with Quanta BioSciences - Affymetrix Receives US FDA Clearance for Gene Profiling Reagents 3. PRODUCT LAUNCHES/TECHNOLOGICAL INNOVATIONS - Agilent Technologies Launches SureScanDx Microarray Scanner - Illumina Introduces Universal Real-Time PCR Reagent Portfolio - Life Technologies Introduces Compendia Oncomine? Next - Generation Sequencing Power Tools - Mirus Bio Develops TransIT-BrCa Transfection Reagent - Affymetrix Launches Axiom? Genotyping Arrays - Affymetrix Introduces SensationPlus FFPE Reagent Kit - Agilent Technologies Unveils Agilent SurePrint G3 Human Gene Expression v2 Microarray - Agilent Unveils Agilent CytoGenomics 1.0 - Agilent Technologies Introduces GeneSpring GX 11. - Bioinformatics Software - Agilent Technologies Unveils New Exon Analysis Solution 4. MARKET PARTICIPANTS - Affymetrix, Inc. - Agendia, Inc. - Agilent Technologies, Inc. - Applied Biosystems, Inc. - Cepheid - Clontech Laboratories, Inc. - Complete Genomics, Inc. - Cytocell Ltd. - DNA LandMarks, Inc. - DNAVision SA - Dynex Technologies, Inc. - Epicentre? Biotechnologies - Eurofins Medigenomix GmbH - Eurogentec SA - Exiqon A/S - GE Healthcare - Geneworks Pty., Ltd. - Genisphere LLC - Illumina, Inc. - Inqaba Biotechnical Industries Pty., Ltd. - Life Technologies Corporation - Mirus Bio LLC - Ocimum Biosolutions Ltd. - Origene Technologies, Inc. - Quanta Biosciences, Inc. - Roche Diagnostics - Saturn Biotech Ltd. - Sequetech Corporation - Sigma-Aldrich Co. LLC - Thermo Fisher Scientific, Inc. 5. APPENDIX For more information visit http://www.researchandmarkets.com/research/3l...expression
Global Genomics Market Forecasts & Opportunities to 2018 - Products, Consumables & Services
M2 - Mon Apr 07, 3:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b5sp23/genomics_market) has announced the addition of the "Global Genomics Market Forecasts & Opportunities to 2018 - Products, Consumables & Services" report to their offering. The global genomics market was valued at $11.11 billion in 2013, and is expected to grow at a CAGR of over 12.0% from 2013 to 2018. The penetration of new markets through the expansion of genomics applications, and advancements in existing technologies plays an important role in attracting new market participants to invest in this market. Next Generation Sequencing (NGS) in personalized medicine and molecular diagnostics is considered as a high growth area for the global genomics market. This new technology provides an affordable and accurate screening solution for genetic mutations. Moreover, the increasing volume of novel genetic tests for personalized medicine and biomarker discovery ensures the continued growth of this market. Tier I and Tier II companies were found to be dominant in the instrument and consumables segments of the genomics market. The genomics market is becoming increasingly consolidated. Among all market players, Roche Diagnostics, Life Technologies, and QIAGEN together accounted for over 47.0% of the revenues earned by the global genomics market in 2013. This concentration of market shares with Tier I market players is expected to challenge market growth. However, technological advancements, and increasing investments are expected to continue to drive the growth of the global genomics market. This report provides comprehensive analysis of market dynamics - drivers, restraints, key market metrics, current market trends, competitive structure, and market revenues and forecasts from 2013 to 2018. It also includes an analysis of mergers and acquisitions in the global genomics market over the last ten years, in addition to technology roadmaps for key technology areas in this market. As a part of the premium insights section, current growth strategies adopted by market participants in the global genomics market have been detailed and analyzed. Scope Products - Instruments - NGS platform - Microarray - RT-PCR Consumables - Genechips - Reagents for DNA Extraction & Purification - Sequencing Services - Sequencing & Microarray Services - Software) Key Topics Covered: - Introduction - Executive Overview - Total Global Genomics Market - Global Genomics Market, By Product Segment - Global Genomics Market, By Technology - Global Genomics Market, By Application - Global Genomics Market, By Geography - Mergers And Acquisitions - Competitive Strategies - Company Profiles - Affymetrix, Inc. - Agilent Technologies, Inc. - Bgi - Bio-Rad Laboratories, Inc. - Cepheid - Ge Healthcare - Illumina, Inc. - Life Technologies, Corp. - Qiagen - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/b5...ics_market
Cepheid Schedules 2014 First Quarter Results Announcement and Webcast
PR Newswire - Thu Apr 03, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2014 first quarter ended March 31, 2014 on Thursday, April 17, 2014, after the close of the market.
Cepheid Announces European Release of Xpert HPV, a 60-Minute Test for Cervical Cancer-Related Human Papillomaviruses
PR Newswire - Wed Apr 02, 6:00AM CDT
Cepheid (NASDAQ: CPHD) today announced the release of Xpert® HPV, a 60-minute test for cervical cancer-related human papillomaviruses to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform. Xpert HPV is a multiplexed test that targets the E6 and E7 oncogenes of 14 cancer-related HPV types and specifically calls out high-risk types 16 and 18/45 in separate detection channels, with 11 other high-risk types detected in a combined channel.
Cepheid Shares Up 37.3% Since SmarTrend's Buy Recommendation (CPHD)
Comtex SmarTrend(R) - Mon Mar 31, 9:39AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2013 at $37.72. In approximately 7 months, Cepheid has returned 37.26% as of today's recent price of $51.78.
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Shares of CPHD Up 37.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 24, 9:14AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2013 at $37.72. In approximately 7 months, Cepheid has returned 37.89% as of today's recent price of $52.02.
Cepheid [CPHD] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Mar 21, 9:00AM CDT
What:
In Recognition of World TB Day 2014, Cepheid and American Lung Association to Ring the NASDAQ Stock Market Opening Bell
PR Newswire - Fri Mar 21, 6:00AM CDT
Cepheid (Nasdaq: CPHD) today announced that James Post, Executive Vice President, North America Commercial Operations for Cepheid, and Harold P. Wimmer, National President and CEO of the American Lung Association, will ring the NASDAQ Opening Bell on March 24th 2014 to commemorate World TB Day.
Cepheid and American Lung Association to Reveal Winner of the 'Ride Against TB' Bike at 2nd Annual New York City TB Walk
PR Newswire - Thu Mar 20, 6:00AM CDT
Cepheid (Nasdaq: CPHD) today announced that the winner of the Ride Against TB bike, a prize in the campaign to benefit the American Lung Association, will be revealed at the 2nd annual New York City World TB Day Walk and Rally on March 22nd. At 9:30 a.m. EDT, Paul Teutul Jr. of Paul Jr. Designs will hand over the keys to the winner of the one-of-a-kind PJD bike at the start line of the World TB Day walk. Cody Connelly, of American Chopper fame, will then ride the custom-designed bike to lead walkers from Union Square in the march down Broadway to the TB rally in Washington Square.
Concise Analysis of the International qPCR and dPCR Instrumentation Market
M2 - Tue Mar 18, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f2m2mm/qpcr_and_dpcr) has announced the addition of the "Concise Analysis of the International qPCR and dPCR Instrumentation Market" report to their offering. This report analyzes the worldwide markets for qPCR and dPCR Instrumentation in US$ Million. The Global market is further analyzed by the following Product Segments and End-Use Markets: Product Segments - qPCR (quantitative Polymerase Chain Reaction), and dPCR (digital Polymerase Chain Reaction); End-Use markets - Educational/Research, Testing Laboratories, and Pharma. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 49 companies including many key and niche players such as: - Agilent Technologies - Biofire Diagnostics, Inc. - Bio-Rad Laboratories, Inc. - Cepheid - Eppendorf AG - Exiqon A/S - F. Hoffmann-La Roche Ltd. - Fluidigm Corporation - Illumina, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MAJOR TRENDS & ISSUES 3. COMPETITION 4. END-USE MARKET ANALYSIS 5. PRODUCT OVERVIEW 6. INSIGHT INTO GLOBAL SPENDING ON LIFE SCIENCES RESEARCH 7. PRODUCT INNOVATIONS/ INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. MIDDLE EAST & AFRICA 7. LATIN AMERICA IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 49 (including Divisions/Subsidiaries - 51) - The United States (29) - Canada (1) - Japan (1) - Europe (19) - Germany (7) - The United Kingdom (2) - Spain (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/f2...r_and_dpcr
Uptrend Call Working As Cepheid Stock Rises 42.8% (CPHD)
Comtex SmarTrend(R) - Fri Mar 14, 4:46PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2013 at $37.72. In approximately 6 months, Cepheid has returned 42.82% as of today's recent price of $53.88.
